

13 March 2023

## Dear Optionholder

## Notice to Optionholders of Non-Renounceable Entitlement Offer

We write to you as the registered holder of options (**Options**) to acquire fully paid ordinary shares in the capital of Osteopore Limited (ACN 630 538 957) (ASX:OSX) (**Osteopore** or **Company**) (**Shares**) as at today's date.

Pursuant to the prospectus lodged with ASX and ASIC on 10 March 2023 (**Prospectus**), Osteopore is undertaking a a non-renounceable entitlement issue of 1 new Share for every 4 existing Shares held by Eligible Shareholders on the record date, being 5.00pm (AWST) on 16 March 2023 (**Record Date**) at an issue price of A\$0.085 per new Share to raise up to approximately A\$2,633,617 (before costs) (**Entitlement Offer**). Participants in the Entitlement Offer will also be issued 1 free quoted option exercisable at A\$0.225 each and expiring on the date that is three years from the date of issue (**Quoted Option**) for every 1 new Share subscribed for under the Entitlement Offer.

Any Securities not validly subscribed for pursuant to the Entitlement Offer will form the Top-Up Offer (**Top-Up Offer**). The issue price for each new Share to be issued under the Top-Up Offer shall be A\$0.085, being the price at which Shares are being offered under the Entitlement Offer. Participants in the Top-Up Offer will also be issued 1 free Quoted Option for every 1 new Share subscribed for under the Top-Up Offer.

Capitalised terms used, but not defined, in this letter have the meaning ascribed to them in the Prospectus.

Any Securities which are not taken up in accordance with the Entitlement Offer and the Top Up Offer (**Remaining Shortfall Securities**) may be applied for by New Investors (**Shortfall Offer**). The issue price of Shares offered under the Shortfall Offer will be A\$0.085 each, which is the issue price at which Shares have been offered to Eligible Shareholders under the Entitlement Offer and the Top Up Offer. Participants in the Shortfall Offer will also be issued 1 free Quoted Option for every 1 new Share subscribed for under the Shortfall Offer. Pursuant to the Shortfall Offer, any Remaining Shortfall Securities may be placed within three months of the Closing Date of the Entitlement Offer and the Top Up Offer.

The Entitlement Offer and Top-Up Offer are available to Eligible Shareholders registered at 5:00pm (AWST) on the Record Date whose registered address is in Australia, New Zealand, Malaysia or Singapore. The Entitlement Offer and Top-Up Offer are not being extended to any shareholders with addresses outside these jurisdictions.

## Your Participation

Pursuant to the terms of the Options you currently hold, there is no entitlement to participate in the Entitlement Offer and Top-Up Offer unless you exercise your Options into Shares, and are entered onto the register as a shareholder of the Company by 5:00pm (AWST) on the Record Date.

If you wish to participate in the Offers, a notice of Options exercise and payment of the Options' exercise price should be lodged with the Company's share registry, Link Market Services Limited with sufficient time to ensure that you are registered as a shareholder of the Company by 5:00pm (AWST) on the Record Date.

If you do not wish to participate in the Offers, no action is required.

## Further details

Details of the Offers are contained in the Prospectus. The Prospectus can be accessed from the ASX and Company websites, <u>www.asx.com.au</u> and <u>www.osteopore.com/investors#asx-announcements</u>



respectively. It is important that you read the Prospectus carefully before deciding whether to exercise your Options and participate in the Offers.

For all enquiries concerning the Offers, please contact the Company Secretary by telephone on +61 8 9482 0500. For all general shareholder enquiries, please contact the Company's Share Registry on 1300 847 879 (within Australia) and +61 1300 847 879 (outside Australia). You should also consult your stockbroker, solicitor, accountant or other suitably qualified professional adviser to evaluate whether or not to participate in the Offers.

Yours faithfully

101

Mark Leong Executive Chairman Osteopore Limited